东诚药业（002675）披露关于锝[99mTc]替曲膦注射液纳入医保目录的公告，12月08日股价下跌0.54%

Core Viewpoint - Dongcheng Pharmaceutical (002675) has seen its stock price decline by 0.54% to 14.8 yuan, with a total market capitalization of 12.204 billion yuan. The company announced that its subsidiary, Nanjing Jiangyuan Andico, has had its product, Technetium-99m (99mTc) tilmanocept injection, included in the National Medical Insurance Directory, which is expected to aid in market promotion and future sales, although it will not significantly impact the company's financial performance until the directory takes effect on January 1, 2026 [1]. Group 1 - As of December 8, 2025, Dongcheng Pharmaceutical's stock closed at 14.8 yuan, down 0.54% from the previous trading day, with a total market value of 12.204 billion yuan [1]. - The stock opened at 15.08 yuan, reached a high of 15.25 yuan, and a low of 14.76 yuan, with a trading volume of 1.03 billion yuan and a turnover rate of 0.93% [1]. - The inclusion of the 99mTc tilmanocept injection in the National Medical Insurance Directory is expected to facilitate market promotion and future sales [1]. Group 2 - The product is indicated for diagnosing adults with suspected coronary artery disease through myocardial perfusion imaging [1]. - The announcement states that the inclusion in the insurance directory will not have a significant impact on the company's operating performance until it is implemented on January 1, 2026 [1].